ArticleClinical journal of gastroenterology2011
Salvage endoscopic submucosal dissection for recurrent esophageal squamous-cell carcinoma after definitive chemoradiotherapy.
Article in Clinical journal of gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
- Coexisting primary tumors from esophageal cancer and myelodysplastic syndromes: A case report.Clinical case reports · 2021Article
- Long-term outcomes of patients with recurrent squamous cell carcinoma of the esophagus undergoing salvage endoscopic resection after definitive chemoradiotherapy.Surgical endoscopy · 2021Article
- Efficacy of traction, using a clip-with-thread, for esophageal endoscopic submucosal dissection for esophageal lesions with fibrosis in an ex vivo pig training model.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2020Article
- Clinicopathological examination of ESD as salvage therapy for esophageal cancer after definitive chemo-radiation therapy.Endoscopy international open · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although concurrent definitive chemoradiotherapy (CRT) is considered a standard treatment for unresectable esophageal carcinoma, CRT is associated with local failure (40-50%), and further interventions are needed in these cases. However, morbidity and mortality rates remain high among patients undergoing salvage esophagectomy for recurrent tumors. Here, we report a rare experience of salvage endoscopic submucosal dissection (ESD) for recurrent esophageal squamous-cell carcinoma (SCC) after definitive CRT. A 55-year-old male was diagnosed with unresectable advanced mid-thoracic esophageal SCC with lymph node metastases involving the trachea. After definitive CRT with cis-diamminedichloroplatinum (CDDP)/5-fluorouracil (5-FU) and 60 Gy irradiation was performed, complete response was obtained. However, a recurrent esophageal SCC was detected in the mid-thoracic esophagus on endoscopy performed 6 months after CRT. The tumor was resected en bloc using ESD without any complications. There was no recurrence for 4 months after ESD. Salvage ESD may be a safe and effective treatment for recurrent esophageal SCC after CRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.